Skip to main content
. 2015 Jun 26;3(5):971–978. doi: 10.3892/mco.2015.590

Table II.

Adjusted comparison of GBM survival analysis among different treatment groups.

Treatment groups Survival months estimate, median (range) Adjusted analysis HR (95% CI) P-value
Surgery alone (n=1,094)   2 (0–89) Reference
All other treatments (n=2,665)     8 (0–121) 0.345 (0.320–0.373) <0.0001
HRT with or without TMZ (n=433)   4 (0–33) Reference
SRT with or without TMZ (n=2,204)     9 (1–121) 0.531 (0.477–0.591) <0.0001
HRT without TMZ (n=390)   4 (0–33) Reference
HRT with TMZ (n=43)   3 (1–29) 0.880 (0.639–1.213)   0.4344
TMZ alone (n=28)   6 (1–24) 0.821 (0.558–1.207)   0.3150
SRT without TMZ (n=1,818)     9 (1–121) Reference
SRT with TMZ (n=386) 11 (2–56) 0.863 (0.770–0.967)   0.0111
Surgery, no RT, no TMZ (n=1,094)   2 (0–89) Reference
Surgery, HRT, no TMZ (n=390)   4 (0–33) 0.556 (0.495–0.625) <0.0001
Surgery, SRT, no TMZ (n=1,818)     9 (1–121) 0.320 (0.295–0.347) <0.0001
Surgery, HRT, TMZ (n=43)   3 (1–29) 0.484 (0.356–0.660) <0.0001
Surgery, SRT, TMZ (n=386) 11 (2–56) 0.277 (0.244–0.313) <0.0001
Surgery, no RT, TMZ (n=28)   6 (1–24) 0.434 (0.298–0.633) <0.0001

GBM, glioblastoma multiforme; HR, hazard ratio (adjusted for age and Charlson comorbidity index); CI, Wald confidence interval; TMZ, temozolomide; RT, radiation therapy; HRT, hypofractionated RT; SRT, standard RT.